SMURF2

Across TCGA pan-cancer cohorts, SMURF2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SMURF2 data layer compared with 27 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SMURF2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SMURF2 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

PDAC, HNSC, and CCRCC are the cancer types where SMURF2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.708	0.826	.010	12	view →
HNSC	DFS	Tertile	All	0.355	1.000	.036	6	view →
CCRCC	DFS	Quartile	All	0.784	0.954	.023	3	view →
LUAD	OS	Median	III,IV	0.650	0.251	.035	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SMURF2–PDAC (DFS)

Open the PDAC breakdown →